The mainstay of therapy for FSGS has traditionally included angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), glucocorticoids, and calcineurin inhibitors [7]. Here, ACE is linked to focal segmental glomerulosclerosis.